Crinetics Pharmaceuticals (CRNX) Misses Q1 EPS by 13c

Crinetics Pharmaceuticals (NASDAQ: CRNX) reported Q1 EPS of ($0.93), $0.13 worse than the analyst estimate of ($0.80). Revenue for the quarter came in at $600 thousand versus the consensus estimate of $111.11 thousand.

For earnings history and earnings-related data on Crinetics Pharmaceuticals (CRNX) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)
• Credo Technology shares rise on analyst support and conference comments